Effect of fractional exhaled carbon monoxide on patients with sleep apnea-hypopnea syndrome and its mechanism.

Quanlin Jia, Li Guo, X. Zheng, Guangwei Li, Lu LiuInvestigación 2024 · DOI

TL;DR

This study identifies fractional exhaled carbon monoxide (FeCO) as a potent, non-invasive biomarker for diagnosing Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS). The researchers found that FeCO levels are significantly elevated in OSAHS patients and correlate strongly with systemic inflammatory markers, offering a promising auxiliary tool for clinical screening.

What Problem Does This Paper Address?

Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) is a prevalent sleep disorder characterized by repeated airway obstruction, leading to chronic intermittent hypoxia and systemic inflammation. Currently, the gold standard for diagnosis is polysomnography (PSG)—an expensive, time-consuming, and often inaccessible "sleep study."

There is a critical need for simpler, non-invasive biomarkers that can screen for the disease or monitor its inflammatory progression. The authors investigate whether FeCO—a byproduct of heme metabolism and a known marker of oxidative stress—can fill this gap by reflecting the underlying airway and systemic inflammation present in OSAHS patients.

Methods

The researchers conducted a comparative clinical study involving 198 participants divided into four groups: OSAHS (n=48), Asthma (n=50), COPD (n=52), and Healthy controls (n=48).

Key measurements included:

  • FeCO Concentration: Measured using a U-breath BA200 breath analyzer.
  • Inflammatory Markers: Blood samples were analyzed for eosinophil (Eos) counts, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
  • Pulmonary Function: Standard spirometry was used to measure FEV1 (forced expiratory volume in one second) and the FEV1/FVC ratio.
  • Statistical Analysis: The team employed Pearson correlation to find relationships between markers and Receiver Operating Characteristic (ROC) curves to determine diagnostic accuracy.

Datasets

The study utilized a primary clinical dataset collected from patients at the Respiratory Department of Shanxi Changzhi Second People’s Hospital between February 2021 and October 2022. No external or public benchmarks were used.

Key Insights and Ideas

  • FeCO as an Inflammatory Proxy: The study confirms that FeCO isn't just a metabolic byproduct; it serves as a measurable signal of the oxidative stress and chronic inflammation triggered by the repeated hypoxia events in OSAHS.
  • The "Inflammation Profile": While OSAHS patients showed higher FeCO and inflammatory markers than healthy individuals, their levels were still slightly lower than the asthma group. This suggests that while OSAHS involves significant inflammation, the pathway may differ from the high-allergic inflammatory response seen in asthma.
  • Independence from Lung Mechanics: Interestingly, FeCO levels did not correlate with lung function (FEV1). This implies that airway inflammation in OSAHS can be significant even when traditional mechanical lung function remains relatively "normal" or only mildly impaired.
  • Diagnostic Potential: The high sensitivity and specificity suggest that a simple breath test could potentially flag high-risk OSAHS patients before they ever reach a sleep lab.

Key Results

  • Elevated FeCO: FeCO levels in the OSAHS group were significantly higher than in the healthy and COPD groups (p < 0.05).
  • Strong Correlations: FeCO showed strong positive correlations with Eos (r = 0.725), ESR (r = 0.562), and CRP (r = 0.762) in OSAHS patients.
  • Diagnostic Accuracy: The ROC curve analysis for FeCO in diagnosing OSAHS yielded an Area Under the Curve (AUC) of 0.824, with a sensitivity of 0.857 and a specificity of 0.835.
  • Lung Function: OSAHS patients exhibited higher FEV1/FVC ratios than COPD patients, indicating that their airway obstruction is distinct from the chronic airflow limitation seen in COPD.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Size: The study was limited to 198 subjects from a single center; larger, multi-center trials are needed to validate these findings.
  • Demographic Variables: Potential confounding factors like age and gender differences across the groups were not fully controlled for in the analysis.
  • Threshold Optimization: While the diagnostic value is high, the paper notes that more research is required to optimize specific diagnostic thresholds for clinical practice.
  • Mechanistic Depth: Further studies are needed to explore the exact physiological pathways linking intermittent hypoxia to specific FeCO production rates in the upper vs. lower airways.

Summary updated

Abstract

Sleep-disordered breathing (SDB) is a common sleep disorder as-sociated with chronic airway inflammation and lung function impairment. This article aimed to investigate the fractional exhaled carbon monoxide (FeCO) expression level in obstructive sleep apnea-hypopnea syndrome (OSAHS) and its correlation with disease indicators. Subjects with OSAHS, asthma, chronic obstructive pulmonary disease (COPD), and healthy subjects were selected to collect clinical data. FeCO concentration, eosinophil (Eos), erythrocyte sed-imentation rate (ESR), C-reactive protein (CRP), FEV1, and FEV1/FVC were measured. The Pearson correlation coefficient and receiver operating charac-teristic (ROC) curve were used for statistical analysis. The FeCO concentra-tion, Eos count, ESR and CRP levels, and lung function in the OSAHS group were higher than the healthy and COPD groups (p&lt;0.05) and slightly lower than the asthma group. FeCO was positively correlated with Eos, ESR, and CRP (p&lt;0.05), but there was no apparent correlation between FeCO and lung func-tion. FeCO has a high sensitivity and specificity in the diagnosis of OSAHS. There is chronic airway inflammation and systemic inflammation in patients with OSAHS. Lung function impairment in patients with OSAHS is mild, but some limitations remain. FeCO may be an auxiliary diagnostic index particu-larly valuable in diagnosing OSAHS.
BibTeX
@inproceedings{jia2024effect,
  author = {Quanlin Jia and Li Guo and X. Zheng and Guangwei Li and Lu Liu},
  title = {{Effect of fractional exhaled carbon monoxide on patients with sleep apnea-hypopnea syndrome and its mechanism.}},
  booktitle = {Investigación},
  year = {2024},
  doi = {10.54817/ic.v65n1a09},
}
Figure